Plain-English translation of NCT07159282 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing a treatment called XWRAP, a single-layer amniotic membrane (a thin patch made from placental tissue), combined with standard wound care for diabetic foot ulcers that haven't healed with conventional treatment. You would be eligible if you were already in another study called CAMPX, received only standard care (not the new treatment), and your ulcer didn't close within 12 weeks. This trial offers a second chance to try the new treatment.
Many people with diabetes develop foot ulcers that won't heal with standard care alone, putting them at risk of serious infection and even amputation. This trial is testing whether adding a placental tissue patch can help these stubborn wounds finally close and improve outcomes.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive the placental membrane patch (XWRAP) applied to your target foot ulcer, along with standard wound care. You will need to attend weekly study visits so the research team can monitor how your wound is healing. You must continue using the prescribed offloading method (keeping pressure off the wound) throughout the study. The team will track whether the patch, combined with standard care, helps your ulcer finally close.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
United States